- Trials with a EudraCT protocol (959)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
959 result(s) found for: Hepatitis C Virus AND Hepatitis C.
Displaying page 29 of 48.
EudraCT Number: 2007-000814-35 | Sponsor Protocol Number: SAEI_IFN_1 | Start Date*: 2007-12-04 |
Sponsor Name:Luis Fernando López Cortés | ||
Full Title: Eficacia de dosis bajas de interferón pegilado alfa-2a junto con ribavirina en el tratamiento de la hepatopatía crónica por virus C (genotipos 2 o 3) en pacientes coinfectados por el VIH (Efficacy ... | ||
Medical condition: Pacientes con hepatitis crónica o cirrosis compensada por virus C (genotipos 2 o 3) coinfectados por el VIH. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005023-33 | Sponsor Protocol Number: 1182.99 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim France SAS | |||||||||||||
Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... | |||||||||||||
Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000281-38 | Sponsor Protocol Number: LEG-SIL-LTX-05 | Start Date*: 2014-03-25 | |||||||||||
Sponsor Name:Rottapharm | |||||||||||||
Full Title: A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon® Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver... | |||||||||||||
Medical condition: Recurrent Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004551-32 | Sponsor Protocol Number: AI444-314 | Start Date*: 2015-11-26 | ||||||||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | ||||||||||||||||||
Full Title: Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety | ||||||||||||||||||
Medical condition: Therapy for chronic HCV-infected renal transplant patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000570-35 | Sponsor Protocol Number: 01-2015 | Start Date*: 2016-02-10 | |||||||||||||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||||||||||||
Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration. | |||||||||||||||||||||||
Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005293-70 | Sponsor Protocol Number: MS04.03 | Start Date*: 2006-06-19 |
Sponsor Name:Emergent Product Development UK Ltd | ||
Full Title: A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of 108 CFU, 109 CFU and 1010 CFU of M04NM11 in patients who have chronic Hepatitis B infection. | ||
Medical condition: Chronic hepatitis B virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001739-35 | Sponsor Protocol Number: SOFT-preOLT | Start Date*: 2014-08-25 | |||||||||||
Sponsor Name:Università di Modena e ReggioEmilia | |||||||||||||
Full Title: An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant in HIV-HCV infected pa... | |||||||||||||
Medical condition: Individuals with HIV-HCV co-infection and end-stage liver disease, with an indication for liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005506-23 | Sponsor Protocol Number: NV18209 | Start Date*: 2006-04-28 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1... | ||
Medical condition: Pacientes con virus de la Hepatitis C crónica (HCC) del genotipo 1 coinfectados por virus de la inmunodeficiencia humana de tipo 1 (VIH-1). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003736-22 | Sponsor Protocol Number: M17-142 | Start Date*: 2020-07-08 |
Sponsor Name:AbbVie Inc. | ||
Full Title: Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects | ||
Medical condition: Hepatitis C virus (HCV) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-003729-27 | Sponsor Protocol Number: 0.8 | Start Date*: 2013-11-15 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin | ||
Medical condition: Genotype 3 HCV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002341-30 | Sponsor Protocol Number: 1705-VLC-030-JG | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:INSTITUTO VALENCIANO DE INFERTILIDAD (IVI) | |||||||||||||
Full Title: Usefulness of medroxyprogesterone acetate in the follicular phase for ovarian donors to prevent premature luteinization | |||||||||||||
Medical condition: prevent premature luteinitation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005616-14 | Sponsor Protocol Number: M13-596 | Start Date*: 2016-05-31 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 ... | ||
Medical condition: Hepatitis C Virus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004594-32 | Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 | Start Date*: 2022-02-16 | |||||||||||
Sponsor Name:IO Biotech ApS | |||||||||||||
Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv... | |||||||||||||
Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000203-34 | Sponsor Protocol Number: Khronos | Start Date*: 2005-05-06 |
Sponsor Name:Enrique Ortega González | ||
Full Title: Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks versus 48 weeks of treatment in patients with chronic hepatitis C genotype II and/or III coinfected w... | ||
Medical condition: Hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004268-38 | Sponsor Protocol Number: Transplant_ABT-1 | Start Date*: 2014-10-27 | ||||||||||||||||
Sponsor Name:Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | ||||||||||||||||||
Full Title: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001449-93 | Sponsor Protocol Number: 110031 | Start Date*: 2015-06-17 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, observer-blind follow-up study with two groups to assess the reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine (GSK1024850... | ||
Medical condition: Healthy volunteers (Booster immunization of healthy children previously primed with three doses of pneumococcal conjugate vaccine or a two-dose catch-up immunization in unprimed children previously... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-001003-32 | Sponsor Protocol Number: 1 | Start Date*: 2021-07-28 |
Sponsor Name:Antwerp University Hospital | ||
Full Title: Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections | ||
Medical condition: Chronic Hepatitis B Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004699-19 | Sponsor Protocol Number: P04438 | Start Date*: 2006-02-21 |
Sponsor Name:Dr. V. Soriano | ||
Full Title: “Estudio piloto, abierto, comparativo y multicéntrico de 2 brazos para evaluar la eficacia y seguridad de un período de extensión de 12 semanas con peginterferon α-2b y ribavirina versus un brazo d... | ||
Medical condition: Hepatitis C Crónica | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001363-37 | Sponsor Protocol Number: RBHP_2016_ABERGEL | Start Date*: 2016-11-18 |
Sponsor Name:CHU de Clermont-Ferrand | ||
Full Title: A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-seve... | ||
Medical condition: viral hepatitis C | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002845-46 | Sponsor Protocol Number: AL-335-604 | Start Date*: 2017-02-03 | |||||||||||||||||||||
Sponsor Name:Alios BioPharma, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ... | |||||||||||||||||||||||
Medical condition: Chronic Hepatitis C infection | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
